Publication | Closed Access

Active targeted Janus nanoparticles enable anti-angiogenic drug combining chemotherapy agent to prevent postoperative hepatocellular carcinoma recurrence

NanoparticlesNanomedicineDrug TargetingOncologyEngineeringMedicineChemotherapy AgentNano-drug DeliveryTumor TargetingBiomedical EngineeringPharmacologyRadiation OncologyTumor Microenvironment